Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway

Yang, Xue; Feng, Ying; Liu, Yao; Ye, Xieqiong; Ji, Xiaomin; Sun, Le; Gao, Fangyuan; Zhang, Qun; Li, Yuxin; Zhu, Bingbing; Wang, Xianbo

doi:10.1016/j.phymed.2021.153575

Public

Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway

Published in Phytomedicine • Apr 18, 2021

Authors:

Xue Yang

Ying Feng

Yao Liu

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a common malignant tumor with limited treatment options. Conventional antitumor therapy combined with traditional Chinese medicine (TCM) to limit tumor progression has gradually become the focus of complementary and alternative therapies for HCC treatmen...

Subject

Hepatocellular carcinoma

Cancer research

Protein kinase B

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!